Astellas Pharma Inc.’s zolbetuximab, a monoclonal antibody targeting Claudin 18.2, met the primary endpoint of progression-free survival in the phase III Spotlight trial in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, according to top-line data.
Kirsten rat sarcoma viral oncogene (KRAS) is one of the GTPases from the RAS family activating signaling pathways that regulate cell functions. KRAS mutation of glycine to aspartate at position 12 (G12D) is a common mutation in pancreatic ductal adenocarcinoma, colorectal cancer, lung adenocarcinoma and other solid tumors. ASP-3082 is a proteolysis targeting chimera (PROTAC) under development by Astellas Pharma Inc. The company has presented the first in vitro and in vivo results of this new compound.
Astellas Pharma Inc. has invested $50 million in Taysha Gene Therapies Inc. in exchange for 15% of the company and exclusive options to in-license Taysha’s lead gene therapy candidates, TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy.
Researchers from Astellas Pharma Inc. presented preclinical data for the novel 5-HT5A receptor antagonist, ASP-5736, being developed for the treatment of fragile X syndrome (FXS).
Astellas Pharma Inc. has described new quinazoline GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer. An exemplified compound degraded KRAS(G12D) mutant expressed in human pancreatic AsPC-1 cancer cells (DC50 = 37 nM) in ELISA assays. An exemplified compound degraded KRAS(G12D) mutant expressed in human pancreatic AsPC-1 cancer cells (DC50 = 37 nM) in ELISA assays. It inhibited 3D anchorage-independent proliferation of KRAS(G12D) mutant-positive AsPC-1 cancer cells (IC50 = 23 nM) in Celltiter-Glo assays.
The U.S. FDA has placed a clinical hold on Astellas Pharma Inc.’s Fortis phase I/II trial evaluating AT-845 following a serious adverse event of peripheral sensory neuropathy in one of the trial participants. AT-845 is an adeno-associated virus (AAV) gene replacement therapy being studied in adults with late-onset Pompe disease.
Astellas Pharma Inc. and Sutro Biopharma Inc. signed an exclusive global licensing deal under which Sutro will develop immunostimulatory antibody-drug conjugates (iADCs) for three biological targets for Astellas.
The U.S. FDA has placed a clinical hold on Astellas Pharma Inc.’s Fortis phase I/II trial evaluating AT-845 following a serious adverse event of peripheral sensory neuropathy in one of the trial participants. AT-845 is an adeno-associated virus (AAV) gene replacement therapy being studied in adults with late-onset Pompe disease.
When he first stepped into the field of glycoproteomics, particularly the potential of truncated O-glycans as cancer targets, Constantine Theodoropulos, CEO of Go Therapeutics Inc., said the reaction from peers was less than encouraging.
